Frontiers in Medicine 2026 Review: Antimicrobial Peptides Pull Double Duty as Anticancer Agents and Vaccine Adjuvants
A Frontiers in Medicine review published in 2026 consolidates the case for antimicrobial peptides (AMPs) as anticancer therapeutics and vaccine adjuvants. The cationic, amphipathic architecture that makes AMPs effective against bacterial membranes also enables selective electrostatic interactions with negatively charged malignant cell membranes — driving rapid membrane disruption and cell lysis. Beyond direct membrane effects, the review documents AMP-induced inhibition of DNA replication and protein synthesis, mitochondrial dysfunction, and tumor angiogenesis suppression. The piece also catalogs AMPs with adjuvant properties that boost vaccine immune responses against cancer and infectious disease. The work joins the Houston Methodist CAMPER MRSA paper, the Nature Communications few-shot Acinetobacter pipeline, and the Manchester penicillin-biosynthesis paper as part of the AMP wave through April–May 2026.